MARKET

ATRA

ATRA

Atara Biotherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.68
-0.47
-3.32%
After Hours: 13.68 0 0.00% 17:04 12/05 EST
OPEN
14.15
PREV CLOSE
14.15
HIGH
14.39
LOW
13.59
VOLUME
411.00K
TURNOVER
--
52 WEEK HIGH
43.93
52 WEEK LOW
10.38
MARKET CAP
740.78M
P/E (TTM)
-2.2450
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ATRA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ATRA News

  • Iovance Biotherapeutics: Solving The Solid Tumors Conundrum
  • Seeking Alpha - Article.6d ago
  • Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference
  • GlobeNewswire.11/26 21:00
  • Investing In The Holy Grail Of Cancer Treatment: Immunotherapy
  • Seeking Alpha - Article.11/22 18:34
  • Turnaround In Progress: Key Takeaways From Atara Biotherapeutics' Q3 Earnings Call
  • Seeking Alpha - Article.11/14 17:33

More

Industry

Biotechnology & Medical Research
-0.70%
Pharmaceuticals & Medical Research
-0.19%

Hot Stocks

Name
Price
%Change

About ATRA

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.
More

Webull offers Atara Biotherapeutics Inc (ATRA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.